Generali Asset Management SPA SGR Sells 32,367 Shares of Merck & Co., Inc. $MRK

Key Points

• Generali Asset Management SPA SGR reduced its Merck stake by 9.5% in the fourth quarter, selling 32,367 shares and leaving it with 308,173 shares valued at about $32.4 million.
• Despite that sale, Merck remains widely held by institutions, which own 76.07% of the company’s stock. Other funds also reported buying or adding to positions during the quarter.
• Merck recently posted a quarterly earnings beat, with EPS of -$1.28 versus estimates of -$1.47 and revenue of $16.29 billion topping expectations, while analysts have largely maintained a Moderate Buy outlook with an average price target of $128.18.

Generali Asset Management SPA SGR lessened its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 9.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 308,173 shares of the company's stock after selling 32,367 shares during the quarter. Merck & Co., Inc. accounts for approximately 0.7% of Generali Asset Management SPA SGR's portfolio, making the stock its 26th largest position. Generali Asset Management SPA SGR's holdings in Merck & Co., Inc. were worth $32,438,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Barnes Dennig Private Wealth Management LLC increased its stake in Merck & Co., Inc. by 302.3% during the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company's stock valued at $30,000 after purchasing an additional 266 shares in the last quarter. United Financial Planning Group LLC bought a new stake in Merck & Co., Inc. during the 3rd quarter valued at $31,000. Wealth Watch Advisors INC bought a new stake in Merck & Co., Inc. during the 3rd quarter valued at $34,000. Dunhill Financial LLC increased its stake in Merck & Co., Inc. by 83.0% during the 3rd quarter. Dunhill Financial LLC now owns 419 shares of the company's stock valued at $35,000 after purchasing an additional 190 shares in the last quarter. Finally, Silicon Valley Capital Partners boosted its holdings in Merck & Co., Inc. by 160.5% during the 3rd quarter. Silicon Valley Capital Partners now owns 422 shares of the company's stock worth $35,000 after acquiring an additional 260 shares during the last quarter. Institutional investors own 76.07% of the company's stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck published a Science paper describing a scalable, enzyme-driven synthesis for its investigational oral PCSK9 inhibitor enlicitide decanoate — a notable R&D milestone that supports the commercial potential of a new oral lipid-lowering modality. Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate
• Positive Sentiment: Merck’s BioReliance unit inked a five‑year deal to be the sole testing provider for Genetix Biotherapeutics’ FDA‑approved gene therapies — adds recurring, commercial‑stage service revenue and reinforces Merck’s role in cell & gene therapy commercialization. Merck Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene Therapies
• Positive Sentiment: Merck completed the Terns acquisition to expand its chronic myeloid leukemia (CML) pipeline; the deal and FDA breakthrough designation for a TERN asset strengthen oncology pipeline optionality. MSD concludes Terns acquisition to expand CML pipeline
• Positive Sentiment: Analysts and brokers showed support after Merck’s Q1 beat — one analyst nudged the price target higher and BMO reiterated a buy — giving near‑term fundamental backing to the stock. Analyst Raises Merck (MRK) Price Target by $1 After Beating Q1 Estimates BMO Capital Remains a Buy on Merck & Company (MRK)
• Neutral Sentiment: Merck Animal Health selected Salesforce’s Agentforce Life Sciences for omnichannel engagement — a strategic IT/customer‑engagement win but with modest near‑term financial impact versus drug/cell‑therapy drivers. Salesforce AI Win With Merck Highlights Real World Platform Adoption
• Neutral Sentiment: Citigroup initiated coverage with a "neutral" rating and a $125 price target — supportive of upside but not a strong buy signal; highlights mixed analyst views on valuation vs. growth. Citigroup Initiates Coverage
• Negative Sentiment: Sector competitors posted robust oncology and diabetes results (J&J oncology growth; Eli Lilly’s blockbuster Mounjaro sales), underscoring competitive pressure in key therapeutic areas and possibly contributing to profit‑taking and relative valuation compression for Merck. Sector Competitive Moves Darzalex, Erleada & New Drugs Keep J&J's Oncology Engine Charged in Q1 Eli Lilly Now Has the World's Best-Selling Drug -- But Does That Make the Stock a No-Brainer Buy?

Merck & Co., Inc. Price Performance

MRK opened at $112.22 on Friday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.30. The company has a market capitalization of $277.17 billion, a price-to-earnings ratio of 31.61, a P/E/G ratio of 2.56 and a beta of 0.18. The firm's fifty day moving average price is $117.07 and its two-hundred day moving average price is $108.31. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $125.14.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.47) by $0.19. The firm had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business's revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, analysts anticipate that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Insider Transactions at Merck & Co., Inc.

In related news, EVP Jennifer Zachary sold 121,573 shares of the business's stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $119.15, for a total value of $14,485,422.95. Following the transaction, the executive vice president directly owned 68,916 shares of the company's stock, valued at approximately $8,211,341.40. The trade was a 63.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Chirfi Guindo sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the sale, the chief marketing officer owned 70,615 shares of the company's stock, valued at approximately $8,361,522.15. The trade was a 12.40% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.17% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Wolfe Research raised shares of Merck & Co., Inc. from a "peer perform" rating to an "outperform" rating and set a $135.00 price objective on the stock in a report on Thursday, January 8th. JPMorgan Chase & Co. lifted their price objective on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an "overweight" rating in a report on Monday, April 6th. UBS Group lifted their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a report on Monday, April 13th. Citigroup assumed coverage on shares of Merck & Co., Inc. in a report on Wednesday. They set a "neutral" rating and a $125.00 price objective on the stock. Finally, Cantor Fitzgerald lifted their price objective on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a "neutral" rating in a report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat, Merck & Co., Inc. has an average rating of "Moderate Buy" and an average price target of $128.18.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.